Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review
Adult mesenchymal stem cells (MSCs) are being investigated further for their use in stem cell therapies. However, as they are found in very low numbers in adult tissue, expansion in vitro is required to produce desired MSC numbers for clinical application. The need for effective cell-based therapies...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2012/465259 |
id |
doaj-5265cbd93d2c44b48b7fce87c4cd66cb |
---|---|
record_format |
Article |
spelling |
doaj-5265cbd93d2c44b48b7fce87c4cd66cb2020-11-24T22:41:34ZengHindawi LimitedStem Cells International1687-966X1687-96782012-01-01201210.1155/2012/465259465259Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature ReviewE. Fossett0W. S. Khan1University College London Institute for Orthopaedics and Musculoskeletal Sciences, Royal National Orthopaedic Hospital, Stanmore HA7 4LP, UKUniversity College London Institute for Orthopaedics and Musculoskeletal Sciences, Royal National Orthopaedic Hospital, Stanmore HA7 4LP, UKAdult mesenchymal stem cells (MSCs) are being investigated further for their use in stem cell therapies. However, as they are found in very low numbers in adult tissue, expansion in vitro is required to produce desired MSC numbers for clinical application. The need for effective cell-based therapies is increasing due to a rise in the ageing population, increasing the prevalence of musculoskeletal disorders. This review investigates how factors, age and gender of donor, as well as seeding density can affect MSC expansion. Age and gender of donor have received mixed results from studies, whereas seeding density studies have produced consistent results for numerous MSC sources, favouring lower seeding densities. Further research is required to reduce the risk of infection, loss of cell characterisation in cell culture, and making cell-based therapies more cost effective through creating rapid expansion of MSCs regardless of patient factors.http://dx.doi.org/10.1155/2012/465259 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
E. Fossett W. S. Khan |
spellingShingle |
E. Fossett W. S. Khan Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review Stem Cells International |
author_facet |
E. Fossett W. S. Khan |
author_sort |
E. Fossett |
title |
Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review |
title_short |
Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review |
title_full |
Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review |
title_fullStr |
Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review |
title_full_unstemmed |
Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review |
title_sort |
optimising human mesenchymal stem cell numbers for clinical application: a literature review |
publisher |
Hindawi Limited |
series |
Stem Cells International |
issn |
1687-966X 1687-9678 |
publishDate |
2012-01-01 |
description |
Adult mesenchymal stem cells (MSCs) are being investigated further for their use in stem cell therapies. However, as they are found in very low numbers in adult tissue, expansion in vitro is required to produce desired MSC numbers for clinical application. The need for effective cell-based therapies is increasing due to a rise in the ageing population, increasing the prevalence of musculoskeletal disorders. This review investigates how factors, age and gender of donor, as well as seeding density can affect MSC expansion. Age and gender of donor have received mixed results from studies, whereas seeding density studies have produced consistent results for numerous MSC sources, favouring lower seeding densities. Further research is required to reduce the risk of infection, loss of cell characterisation in cell culture, and making cell-based therapies more cost effective through creating rapid expansion of MSCs regardless of patient factors. |
url |
http://dx.doi.org/10.1155/2012/465259 |
work_keys_str_mv |
AT efossett optimisinghumanmesenchymalstemcellnumbersforclinicalapplicationaliteraturereview AT wskhan optimisinghumanmesenchymalstemcellnumbersforclinicalapplicationaliteraturereview |
_version_ |
1725701814085484544 |